Title:
METHOD FOR DIAGNOSING EARLY AND CLASSIFYING STAGES OF ALZHEIMER'S DISEASE AND DETERMINING AMYLOID BETA ACCUMULATION IN BRAIN BY USING TAU PROTEIN-DERIVED PHOSPHORYLATED PEPTIDE
Document Type and Number:
WIPO Patent Application WO/2024/005591
Kind Code:
A1
Abstract:
The present invention relates to a method for diagnosing Alzheimer's disease early by using a tau protein-derived phosphorylated peptide and, more specifically, to a method for diagnosing early or classifying stages of Alzheimer's disease and determining amyloid beta accumulation in the brain by measuring the phosphorylation level of tau protein in a biological sample. The tau protein-derived phosphorylated peptide quantification method according to the present invention can effectively diagnosis early or classify stages of Alzheimer's disease and determine amyloid beta accumulation in the brain.
Inventors:
PARK ZEE-YONG (KR)
JANG SE HWAN (KR)
KIM YOU RIM (KR)
HWANG DAEHEE (KR)
LEE KUNHO (KR)
JANG SE HWAN (KR)
KIM YOU RIM (KR)
HWANG DAEHEE (KR)
LEE KUNHO (KR)
Application Number:
PCT/KR2023/009231
Publication Date:
January 04, 2024
Filing Date:
June 30, 2023
Export Citation:
Assignee:
GWANGJU INST SCIENCE & TECH (KR)
SEOUL NAT UNIV R&DB FOUNDATION (KR)
UNIV CHOSUN IACF (KR)
SEOUL NAT UNIV R&DB FOUNDATION (KR)
UNIV CHOSUN IACF (KR)
International Classes:
G01N33/68; G01N30/02
Foreign References:
| JP2018519505A | 2018-07-19 | |||
| KR20210004996A | 2021-01-13 |
Other References:
KARIKARI THOMAS K; PASCOAL THARICK A; ASHTON NICHOLAS J; JANELIDZE SHORENA; BENEDET ANDRéA LESSA; RODRIGUEZ JUAN LANTERO; CHA: "Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts", THE LANCET NEUROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 5, 22 April 2020 (2020-04-22), AMSTERDAM, NL, pages 422 - 433, XP086143502, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(20)30071-5
QIN WEI, LI FANGYU, JIA LONGFEI, WANG QI, LI YING, WEI YIPING, LI YAN, JIN HONGMEI, JIA JIANPING: "Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage", FRONTIERS IN AGING NEUROSCIENCE, FRONTIERS RESEARCH FOUNDATION, CH, vol. 14, 13 June 2022 (2022-06-13), CH , pages 900773, XP093123868, ISSN: 1663-4365, DOI: 10.3389/fnagi.2022.900773
SUÁREZ‐CALVET MARC; KARIKARI THOMAS K; ASHTON NICHOLAS J; LANTERO RODRÍGUEZ JUAN; MILÀ‐ALOMÀ MARTA; GISPERT JUAN DOMINGO; SALVADÓ : "Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected", EMBO MOLECULAR MEDICINE, WILEY-BLACKWELL, US, vol. 12, no. 12, 7 December 2020 (2020-12-07), US , XP055821777, ISSN: 1757-4676, DOI: 10.15252/emmm.202012921
QIN WEI, LI FANGYU, JIA LONGFEI, WANG QI, LI YING, WEI YIPING, LI YAN, JIN HONGMEI, JIA JIANPING: "Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage", FRONTIERS IN AGING NEUROSCIENCE, FRONTIERS RESEARCH FOUNDATION, CH, vol. 14, 13 June 2022 (2022-06-13), CH , pages 900773, XP093123868, ISSN: 1663-4365, DOI: 10.3389/fnagi.2022.900773
SUÁREZ‐CALVET MARC; KARIKARI THOMAS K; ASHTON NICHOLAS J; LANTERO RODRÍGUEZ JUAN; MILÀ‐ALOMÀ MARTA; GISPERT JUAN DOMINGO; SALVADÓ : "Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected", EMBO MOLECULAR MEDICINE, WILEY-BLACKWELL, US, vol. 12, no. 12, 7 December 2020 (2020-12-07), US , XP055821777, ISSN: 1757-4676, DOI: 10.15252/emmm.202012921
Attorney, Agent or Firm:
HANOL INTELLECTUAL PROPERTY & LAW (KR)
Download PDF: